SEATTLE — In this video from the ARVO meeting, Jay Chhablani, MD, discusses data on pan-VEGF blockers and tyrosine kinase inhibitors for age-related macular degeneration.
In poster presentations, EyePoint Pharmaceuticals discussed its extended delivery systems, while Ocular Therapeutix presented data on tyrosine kinase inhibitors.
“Some of the phase 2 trial data on pan-VEGF blockers, as well as tyrosine kinase inhibitors, were presented [at the ARVO meeting],” Chhablani, professor of ophthalmology at University of Pittsburgh School of Medicine, said. “We are really